Identifying EGFR-Expressed Cells and Detecting EGFR Multi-Mutations at Single-Cell Level by Microfluidic Chip
暂无分享,去创建一个
Weikai Zhang | Zewen Wei | Zihua Wang | Zhi Y. Hu | Ren Li | Chunyan Yue | Yan Ma | Mingxing Zhou | Jine Li | Hailin Peng
[1] C. Culbertson,et al. Cellular Analysis Using Microfluidics. , 2018, Analytical chemistry.
[2] Je-Gun Joung,et al. Vertical Magnetic Separation of Circulating Tumor Cells for Somatic Genomic-Alteration Analysis in Lung Cancer Patients , 2016, Scientific Reports.
[3] K. Nishio,et al. Association of EGFR Exon 19 Deletion and EGFR-TKI Treatment Duration with Frequency of T790M Mutation in EGFR-Mutant Lung Cancer Patients , 2016, Scientific Reports.
[4] Dahai Ren,et al. Multiplexed Analysis for Anti-Epidermal Growth Factor Receptor Tumor Cell Growth Inhibition Based on Quantum Dot Probes. , 2016, Analytical chemistry.
[5] Birgit Kasch,et al. Next Generation , 2016, Im OP.
[6] Chwee Teck Lim,et al. Microfluidic enrichment for the single cell analysis of circulating tumor cells , 2016, Scientific Reports.
[7] Han Gardeniers,et al. Microfluidic device for DNA amplification of single cancer cells isolated from whole blood by self-seeding microwells. , 2015, Lab on a chip.
[8] Ling Xu,et al. Single-cell codetection of metabolic activity, intracellular functional proteins, and genetic mutations from rare circulating tumor cells. , 2015, Analytical chemistry.
[9] Sijia Lu,et al. Uniform and accurate single-cell sequencing based on emulsion whole-genome amplification , 2015, Proceedings of the National Academy of Sciences.
[10] Chun-Ming Tsai,et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] Qinghua Zhou,et al. Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[13] L. Mazutis,et al. Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. , 2011, Lab on a chip.
[14] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[15] A. Gazdar,et al. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors , 2009, Oncogene.
[16] T. Mok,et al. Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non–Small Cell Lung Cancer Patients , 2009, Clinical Cancer Research.
[17] Alona Muzikansky,et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] M. Meyerson,et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.
[19] A. Barabasi,et al. The human disease network , 2007, Proceedings of the National Academy of Sciences.
[20] H. Tournaye,et al. The efficiency of magnetic-activated cell sorting and fluorescence-activated cell sorting in the decontamination of testicular cell suspensions in cancer patients. , 2007, Human reproduction.
[21] William C Hahn,et al. Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants , 2005, PLoS medicine.
[22] J. Minna,et al. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. , 2005, Cancer research.
[23] Daniel A. Haber,et al. Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.
[24] S. Störkel,et al. Immunohistochemical Detection of EGFR in Paraffin-embedded Tumor Tissues , 2004, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[25] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[26] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[27] Cynthia Hawkins,et al. Identification of a cancer stem cell in human brain tumors. , 2003, Cancer research.
[28] Lesley Seymour,et al. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. , 2003, The Lancet. Oncology.
[29] R. DePinho,et al. Pancreatic cancer biology and genetics , 2002, Nature Reviews Cancer.
[30] W. Cavenee,et al. Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. , 2001, International journal of oncology.
[31] J. Grandis,et al. Quantitative immunohistochemical analysis of transforming growth factor‐α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck , 1996, Cancer.
[32] L. Jin,et al. Evaluation of 13 short tandem repeat loci for use in personal identification applications. , 1994, American journal of human genetics.
[33] R. Hubert,et al. Whole genome amplification from a single cell: implications for genetic analysis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[34] J. Farndon,et al. EPIDERMAL-GROWTH-FACTOR RECEPTOR STATUS AS PREDICTOR OF EARLY RECURRENCE OF AND DEATH FROM BREAST CANCER , 1987, The Lancet.
[35] S. Cummings,et al. A randomized trial , 2011 .
[36] N. Goldstein,et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[37] S. Keyse,et al. Tyrosine kinase inhibition: an approach to drug development. , 1995, Human & experimental toxicology.